HERG Screening Market Highlights

The HERG Screening Market is witnessing significant growth, propelled by the increasing demand for cardiotoxicity assessment in drug development and safety testing. Cardiotoxicity assessment, particularly focused on evaluating the risk of drug-induced cardiac arrhythmias, is a crucial step in the drug development process. HERG (human ether-a-go-go-related gene) screening plays a pivotal role in this assessment by evaluating the potential of drugs to block the hERG potassium ion channel, which is known to be associated with drug-induced QT prolongation and torsades de pointes arrhythmias. Through high-throughput screening techniques and advanced electrophysiological assays, HERG screening enables pharmaceutical companies and researchers to identify and mitigate cardiotoxic effects early in the drug development process, thereby improving patient safety and reducing the risk of adverse cardiac events associated with new medications.

The size of the HERG Screening Market was estimated at USD 0.9 billion in 2022. The market for HERG screening is anticipated to increase from USD 1.0 billion in 2023 to USD 2.6 billion by 2032, with a compound annual growth rate (CAGR) of 12.50% over the course of the forecast period (2023-2032).

Segment Analysis

Global HERG Screening Market is segmented into Type, i.e., gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels and held the largest market share in the HERG screening market. The global HERG screening market is segmented based on ion channel, further bifurcated into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage-gated ion channel held the largest share in the HERG screening market, whereas ion-gated channel is the fastest-growing segment. The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug application segment is projected to account for a considerable market share.

Regional Analysis

The global HERG screening market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas held the largest share of the HERG screening market. This share can be attributed to technological development and the high prevalence of cardiac disease in the region.

The Europe HERG screening market has been segmented into Western Europe and Eastern Europe. The Western Europe HERG screening market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The major players of these countries are involved in new launches and acquisitions in the HERG screening market. The HERG screening market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The market growth in these countries is attributed to the large pool of patients suffering from cardiac disorders and the need for drug formulation and development to cure these disorders. The Middle East Africa HERG screening market has been divided into the Middle East and Africa.

Key Players

MRFR recognizes the following companies as the Key HERG Screening Market players —Thermo Fisher Scientific, Eurofins Discover X Corporation, Charles River Laboratories, Merck KGaA, Metrion Biosciences Ltd, and Aurora Biomed, Inc.

Key Findings of the Study

·        HERG Screening Market is expected to register a CAGR of 12.50% during the assessment period of 2023 to 2032.

·        The Americas accounted for the largest share of the global HERG screening market due to the presence of prominent players in the US, high uptake rate, and product clearances from regulatory authorities.

·        Based on type, the KCNH2 gene segment accounted for the largest market share.

·        On the basis of ion channel, the voltage-gated ion channel segment is expected to be the fastest-growing segment during the forecast period.

·        Based on application, the antiarrhythmic drug segment is expected to be the largest and fastest-growing segment during the forecast period.

For more information visit at MarketResearchFuture